Following a full submission
AWMSG advice |
|||
| Status: Recommended with restrictions | |||
Tegafur/gimeracil/oteracil (Teysuno®) is recommended as an option for restricted use within NHS Wales in adults for the treatment of advanced gastric cancer when given in combination with cisplatin, when standard triplet therapy is not suitable. |
|||
|
|||
Medicine details |
|||
| Medicine name | Tegafur/gimeracil/oteracil (Teysuno®) | ||
| Formulation | 15 mg / 4.35 mg / 11.8 mg capsule and 20 mg / 5.8 mg / 15.8 mg capsule | ||
| Reference number | 928 | ||
| Indication | Treatment of advanced gastric cancer in adults when given in combination with cisplatin |
||
| Company | Nordic Pharma UK Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Submission type | Full | ||
| Status | Recommended with restrictions | ||
| Advice number | 2613 | ||
| NMG meeting date | 11/09/2013 | ||
| AWMSG meeting date | 16/10/2013 | ||
| Ratification by Welsh Government | 02/12/2013 | ||
| Date of issue | 03/12/2013 | ||
| Date of last review | 01/12/2016 | ||